MGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MeiraGTx Holdings PLC (MGTX) is not a strong buy for a beginner, long-term investor at this moment. The stock lacks immediate positive catalysts, has weak financial performance, and no strong trading signals. While hedge funds are buying, the technical indicators and financial data suggest caution. A hold position is recommended until stronger growth trends or catalysts emerge.
The MACD is negative and expanding, indicating a bearish trend. RSI is at 38.612, which is neutral but leaning toward oversold territory. Moving averages are converging, showing no clear trend. Key support is at 7.251, and resistance is at 8.074. The stock is trading below the pivot point of 7.663, suggesting weakness.
Hedge funds have significantly increased their buying activity by 869.70% over the last quarter. Analysts maintain a Buy rating with price targets of $14 and $20, citing confidence in the company's late-stage gene therapy programs.
The company's financials are weak, with revenue dropping by -96.24% YoY in Q3 2025, and gross margin plummeting by -340.20% YoY. No recent news or congress trading data is available to act as a catalyst. Technical indicators suggest bearish momentum.
In Q3 2025, revenue dropped significantly to $410,000 (-96.24% YoY). Net income improved to -$50.51M (+28.43% YoY), and EPS increased to -0.62 (+12.73% YoY). However, gross margin fell drastically to 23.66 (-340.20% YoY), indicating significant operational challenges.
Analysts maintain a Buy rating with price targets of $14 (BofA) and $20 (H.C. Wainwright). Analysts are optimistic about the company's gene therapy programs and improving biotech sector conditions but express concerns about the sustainability of these trends.
